Navigation Links
Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
Date:5/14/2012

Session: Sunday, June 3, 2012, 11:15 AM – 11:30 AM
  • First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors.
  • Author/Speaker: Emiliano Calvo
  • Location: E Arie Crown Theater

P-LLY

This press release contains forward-looking statements about the potential of ramucirumab, LY900009, LY2228820 dimesylate and LY2780301 and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the products will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
2. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. DiversityInc Names Lilly a Top Company for Diversity
5. Lilly Declares Second-Quarter 2012 Dividend
6. Lilly Diabetes and Walgreens Launch Diabetes Hypoglycemia Awareness Campaign
7. Lillys John Lechleiter Becomes PhRMA Board Chairman; Robert J. Hugin, Ian Read Assume New Posts
8. Lilly Confirms Date and Conference Call for First-Quarter 2012 Financial Results Announcement
9. Lilly Diabetes supports Diabetes Scholars Foundation with $100,000 donation in 2012
10. Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys
11. Boehringer Ingelheim and Lillys new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer ... VPHM).   As a result of the waiver, ... Shire expects to complete the tender offer on January 24, ... satisfaction of all of the remaining conditions to the tender ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Market & Forecast – Worldwide Analysis ... Insulin Pump Market Analysis ... in the market as insulin delivery systems ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/16/2014)... SAN ANTONIO, Texas (April 16, 2014) A team ... The University of Texas Health Science Center at San ... the structure of a protein that helps a common ... Candida albicans causes yeast infections, diaper rashes ... pathogen to infect humans. It can also cause a ...
(Date:4/15/2014)... Scientists have solved a decades-old medical mystery and ... to fight invasive fungal infections, which kill about 1.5 million ... mechanism of action of amphotericin, an antifungal drug that has ... though it is nearly as toxic to human cells as ... report of the new findings appears in Nature ...
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April ... using a novel way to access the heart. ... the United States performing the unique procedure called ... temporarily connecting major blood vessels. , Northern Michigan ... transcaval procedure on July 3, 2013 when traditional ...
(Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
(Date:4/14/2014)... FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... the destruction of human red blood cells exposed ... of autoimmune hemolytic anemia (AIHA). The article entitled ... prevents complement activation induced by cold agglutinin disease ... Blood earlier this month. TNT003 is ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2
... multiple low-energy treatments, combined with a plasma skin regeneration ... appearance, in record healing time. These multiple treatments have ... reduced healing times. ,"Plasma is a unique ... atoms to form an ionized gas," the authors write ...
... 27,000 women adds support to the view that high cholesterol ... even in healthy women with no history of heart disease ... importance of cholesterol levels as a risk factor for stroke, ... are otherwise healthy,” said study author Tobias Kurth, MD, ScD, ...
... over the influence of scantily clad dolls on young minds, ... one important reason for the rise of eating disorders, they ... voiced apprehension regarding the hype created by the media about ... which are known for their hour glass figures and revealing ...
... found evidence that a genetic tendency toward suicide has ... on chromosome 2. The same has been implicated in ... ,“We’re hoping our findings will eventually lead to tests ... suicide,” says Virginia Willour, Ph.D., an assistant professor in ...
... in women years in advance of a medical diagnosis ... ,Epidemiologists at the University at Buffalo in New ... diabetes found in the blood, such as markers of ... are present early on in women who eventually progress ...
... Otolaryngology-Head & Neck Surgery, chronic dizziness may be attributed// to ... study investigated 345 men and women who had suffered dizziness ... the age group of 15 to 89. It was found ... kind of anxiety disorders like migraine or a serious brain ...
Cached Medicine News:Health News:Multiple Low-energy Plasma Skin Treatments Beneficial in Reducing Facial Wrinkles 2Health News:Study Links Attempted Suicide With Genetic Evidence 2Health News:Study Links Attempted Suicide With Genetic Evidence 3Health News:Diabetes Risk Factors Develop Earlier in Women Than Men 2
... accommodate a variety of applications across a ... DestinyPlus is suitable for any laboratory demanding ... a mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per ... full range of chromogenics, the AMAX DestinyPlus ...
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: